Director Mark Steven Davis filed a Form 144 notice on November 18, 2026, disclosing a proposed sale of 6,100 shares of Myriad Genetics Inc common stock through Fidelity Brokerage Services LLC on NASDAQ.

Key Highlights

  • Proposed seller: Mark Steven Davis, a director of Myriad Genetics Inc.
  • Shares proposed for sale: 6,100 shares of common stock, with an aggregate market value of $34,251.50.
  • Approximate date of sale: November 18, 2026, through Fidelity Brokerage Services LLC.
  • Shares outstanding: 95,922,196 shares of common stock, according to the filing.
  • Acquisition history: 2,100 shares were acquired via restricted stock vesting on December 10, 2025, and 4,000 shares via restricted stock vesting on June 4, 2026, both from the issuer as compensation.
  • Prior three-month sales: The filing reports nothing to report for securities sold in the past three months.

Davis Proposes Sale of Restricted Stock Vesting Proceeds at Myriad Genetics

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Mark Steven Davis, identified as a director of Myriad Genetics Inc (NASDAQ:MYGN), disclosed a proposed sale of 6,100 shares of the company's common stock. The filing lists Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, Rhode Island 02917, as the broker for the transaction. The aggregate market value of the shares proposed for sale is stated as $34,251.50.

The filing details two separate acquisition events underlying the shares proposed for sale. The first tranche of 2,100 shares was acquired through restricted stock vesting on December 10, 2025, from the issuer as compensation. The second tranche of 4,000 shares was acquired through restricted stock vesting on June 4, 2026, also from the issuer as compensation. The filing indicates no securities of Myriad Genetics were sold by Davis in the three months preceding this notice.

The notice was signed by Daniel Tucci, described as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Mark Davis. The filing states that the total shares of common stock outstanding at the time of the notice were 95,922,196. The date of notice is listed as November 18, 2026.

What Was Disclosed

Myriad Genetics director Mark Steven Davis filed a Form 144 notice proposing the sale of 6,100 shares of common stock, acquired through two restricted stock vesting events, with an aggregate market value of $34,251.50, through Fidelity Brokerage Services LLC on NASDAQ.